Bone Abstracts

Background: Hyperphosphatemic familial tumoral calcinosis (HFTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is an autosomal recessive disorder due to deficiency of or resistance to intact fibroblast growth factor 23 (FGF23). This leads to hyperphosphatemia, increased renal reabsorption of phosphorus (TRP), and elevated or inappropriately normal 1,25-dihydroxyvitamin D (1,25D). Affected individuals may develop ectopic calcifications and/or diaphyseal hyperostosis. Mutations ...

Multiple myeloma (MM) is associated with lytic bone destruction leading to high fracture incidence in the vertebrae. Accurate assessment of fracture risk is required for physicians to determine the necessity for surgery. This risk is currently determined by examining lesion size or number; however, this method does not consider the biomechanical attributes of the bone. Finite element (FE) modelling can simulate mechanical loading on vertebral bodies, and estimate mechanical in...

Aim: Evaluate the differences with densitometry after 2-year treatment in patients with breast cancer and LBMD.Materials and methods: A 2 year duration longitudinal study was done in patients diagnosed with breast cancer sent to the Rheumatology Osteoporosis Unit in Hospital d’Ontinyent, who required supplements of calcium and vitamin D+bisphosphonates after a risk fracture study. Socio-demographic data, breast tumor characteristics, risk f...

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...

Osteoporotic fractures of the vertebrae are often silent and if left untreated will lead to progressive loss of vertebral body height and significant kyphoscoliosis, with its associated morbidity. However if vertebral fractures (VF) are detected early, treatment with bisphosphonates accelerates healing of prevalent fractures and reduces incident fractures.A survey of members of the British Paediatric and Adolescent Bone Group showed that treatment is sta...

Peak bone mass is a major determinant of osteoporosis risk and subsequent fragility fractures in older age. There is a wide range of factors influencing peak bone mass, ranging from those acting very early in life, for example in utero and periconception, to those acting through childhood and adolescence into young adulthood. In this presentation I will give an overview of some overarching themes and principles of relevance to peak bone mass, using specific clinical scenarios ...

Biographical DetailsNicholas HarveyNicholas Harvey was appointed to a personal chair at the University of Southampton in 2015, and leads, with Professor Cooper and Professor Dennison, an MRC programme focused on the lifecourse epidemiology of bone and joint disease, as part of the MRC Lifecourse Epidemiology Unit. He is working to i) translate epide...

Background: Patients with differentiated thyroid cancer (DTC) are treated with L-thyroxine (L-T4) in relatively hight doses to suppress endogenous TSH levels. Very long-term effect of thyroid hormones supplementation on bone are controversial.Objetive: To study the possible negative effects on bone mineral density (BMD) and bone markers in DTC patients followed in our center.Methods: A 46 po...

Relatively little is known about immediate consequences of continuing vs interrupting long-term bisphosphonate treatment. This report describes changes in bone turnover and BMD in a 1-year, dose-finding trial of the calcium-sensing receptor antagonist MK-5442 in postmenopausal, BP-treated women, randomized to continued alendronate 70 mg weekly, switch to placebo, or switch to MK-5442. Recruited women (n=526) had taken alendronate for ≥12 months and an oral BP fo...

see P475....